But surveillance for XDR-TB has been more limited, as drug susceptibility testing for second-line drugs is not well-standardized and for some drugs is poorly reproducible, while few countries perform such testing within the context of their national TB programs. Priorities for XDR-TB surveillance include facilitating access to reliable susceptibility testing to second-line drugs and incorporating this, together with information about HIV testing, into existing TB surveillance activities.